ASLN News and Press, ASLAN Pharmaceuticals Limited From 09/07/23

SAN MATEO, Calif. and SINGAPORE, Sept. 07, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, today announced that management will give an in-person comp...

2023-08-11 10:24:12 ET ASLAN Pharmaceuticals press release ( NASDAQ: ASLN ): Q2 GAAP EPS of -$0.93. As of June 30, 2023, the Company had cash and cash equivalents of $40.9 million. $12.0 million upfront strategic license payment from Zenyaku received in July, extending the...

Positive topline data reported in July from TREK-AD, a Phase 2b study of eblasakimab that met the primary endpoint across three dose arms with statistical significance. The data established eblasakimab , a potential first-in-class antibody, as the first biologic in...

2023-07-07 12:50:55 ET Gainers: Prestige Wealth ( PWM ) +90% . Castle Biosciences ( CSTL ) +52% . Near Intelligence ( NIR ) +44% . T2 Biosystems ( TTOO ) +37% . Greenidge Generation Holdings ( GREE ) +31% . The Real Good Food...

2023-07-07 10:07:00 ET Gainers: Castle Biosciences ( CSTL ) +43% . CareDx ( CDNA ) +20% . COMPASS Pathways ( CMPS ) +9% . TG Therapeutics ( TGTX ) +9% . KalVista Pharmaceuticals ( KALV ) +8% . Losers: PainReform ( P...

2023-07-06 13:08:25 ET Gainers: EdtechX Holdings Acquisition ( EDTX ) +40% . Mullen Automotive ( MULN ) +35% . Genius Sports Limited ( GENI ) +21% . Incannex Healthcare Limited ( IXHL ) +19% . Sweetgreen ( SG ) +18% . urban-g...

2023-07-06 11:25:40 ET Top-line phase 2b results indicated that ASLAN Pharmaceuticals ( NASDAQ: ASLN ) eblasakimab was effective in treating atopic dermatitis when dosed monthly. Data showed that 600mg of eblasakimab dosed once every four weeks led to 62.7% of patien...

2023-07-06 08:32:06 ET Allarity Therapeutics ALLR -53% after pricing public offering to $11M ASLAN Pharmaceuticals Limited ( ASLN ) -33% to host webcast on July 6, 2023, to discuss phase 2b topline data from TREK-AD trial evaluating Eblasakimab in atopic dermatitis. ...

Eblasakimab is the first biologic in moderate-to-severe atopic dermatitis to demonstrate a competitive efficacy profile with once-monthly dosing from initiation comparable to once every two weeks, supporting advancement to Phase 3. 600mg eblasakimab dosed once every ...

SAN MATEO, Calif. and SINGAPORE, July 05, 2023 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, will host a webcast to discuss the to...